Free
Pain Medicine  |   January 2010
Bupivacaine Inhibits Glutamatergic Transmission in Spinal Dorsal Horn Neurons
Author Affiliations & Notes
  • Kenta Furutani, M.D.
    *
  • Miho Ikoma, M.D., Ph.D.
  • Hideaki Ishii, M.D., Ph.D.
  • Hiroshi Baba, M.D., Ph.D.
  • Tatsuro Kohno, M.D., Ph.D.
    §
  • * Graduate Student, † Assistant Professor, ‡ Professor, Division of Anesthesiology, Niigata University Graduate School of Medical and Dental Sciences. § Associate Professor, Division of Anesthesiology, Niigata University Graduate School of Medical and Dental Sciences; Pain Mechanism Research Group.
Article Information
Pain Medicine / Pain Medicine / Pharmacology
Pain Medicine   |   January 2010
Bupivacaine Inhibits Glutamatergic Transmission in Spinal Dorsal Horn Neurons
Anesthesiology 1 2010, Vol.112, 138-143. doi:10.1097/01.anes.0000365964.97138.9a
Anesthesiology 1 2010, Vol.112, 138-143. doi:10.1097/01.anes.0000365964.97138.9a
What We Already Know about This Topic:
  • ❖ Local anesthetics block sodium channels, but also other membrane-bound proteins.
  • ❖ In simple cell systems, local anesthetics block glutamate receptors of the N  -methyl-d-aspartate type.
What This Article Tells Us That Is New:
  • ❖ Bupivacaine and other local anesthetics, in concentrations found after spinal anesthesia, block N  -methyl-d-aspartate receptors.
  • ❖ Spinal anesthesia may be accompanied by blockade of N  -methyl-d-aspartate receptors, which are important to acute pain and to generation of sensitized states.
IT is well established that local anesthetics block impulses in peripheral nerves through the inhibition of voltage-gated sodium channels. However, the underlying mechanisms of spinal and epidural anesthesia may be more complex than simply the blockade of impulses in nerve roots. Local anesthetics may not only block the impulses in nerve roots, but could also interact with many membrane phospholipids and proteins, including various receptors, and thereby affect a variety of cellular activities.
N  -methyl-d-aspartate (NMDA)–type glutamate receptors are one of the major receptor channel types mediating rapid excitatory neurotransmission in the central nervous system; they also play an important role in central sensitization regarding long-term pain.1,2 Some previous studies have examined the interactions between local anesthetics and NMDA receptors. These have shown that local anesthetics inhibit NMDA receptors in Xenopus  oocytes3,4 and in mouse CA1 pyramidal neurons.5 Furthermore, bupivacaine, a long-acting local anesthetic, inhibits phosphorylated extracellular signal–regulated kinase activation induced by NMDA in the rat spinal cord, as revealed by immunohistochemistry.6 Therefore, local anesthetics may have a direct antinociceptive effect in the spinal dorsal horn by modulating NMDA receptors, and if so, they could play an important role in preventing the development of pain by spinal and epidural anesthesia. Lamina II (substantia gelatinosa [SG]) neurons of the spinal cord preferentially receive thin myelinated AΔ- and unmyelinated C-primary afferent fibers. Both of these fiber types carry nociceptive information and, therefore, are thought to play an important role in modulating nociceptive transmission.7,8 
To test the hypothesis that local anesthetics directly inhibit NMDA receptors in the spinal dorsal horn, we evaluated the action of bupivacaine, a local anesthetic commonly used for spinal, epidural anesthesia and neuraxial blockade, on excitatory NMDA-mediated synaptic responses in the SG of rat spinal cord slices using the whole-cell patch-clamp method.
Materials and Methods
This study was approved by the Animal Care and Use Committee at Niigata University Graduate School of Medical and Dental Sciences (Niigata, Japan). Adult Wistar rats (aged 5–8 weeks) were anesthetized with urethane (1.5 g/kg, intraperitoneal). A dorsal laminectomy was performed, and the lumbosacral segment of the spinal cord with ventral and dorsal roots attached was removed.9,10 The rats were then immediately killed by exsanguination, and the spinal cords were placed in preoxygenated ice-cold Krebs solution. After the arachnoid membrane was removed, the spinal cord was placed in an agar block and mounted on a metal stage. A transverse slice (500 μm thick) was cut on a DTK-1500 microslicer (Dosaka, Japan) and placed on a nylon mesh in the recording chamber. The slice was perfused continuously with Krebs solution (10–20 ml/min) equilibrated with 95% O2and 5% CO2gas mixture at 36°C. The Krebs solution contained 117 mm NaCl, 3.6 mm KCl, 2.5 mm CaCl2, 1.2 mm MgCl2, 1.2 mm NaH2PO4, 25 mm NaHCO3, and 11.5 mm D-glucose. Whole-cell patch-clamp recordings were made from SG neurons in voltage-clamp mode with patch pipette electrodes having a resistance of 10 MΩ. The patch pipette solution contained 110 mm Cs-sulfate, 0.5 mm CaCl2, 2 mm MgCl2, 5 mm EGTA, 5 mm HEPES, 5 mm tetraethylammonium, and 5 mm ATP-Mg salt. Guanosine-5′-O  -(2-thiodiphosphate) (GDP-β-S; 1 mm) was used as a G-protein blocker when necessary. Signals were amplified using an Axopatch 200B amplifier (Molecular Devices, Union City, CA) and were filtered at 2 kHz and digitized at 5 kHz. Data were collected and analyzed using pClamp 10.0 software (Molecular Devices). All experiments were performed in voltage-clamp mode at a holding potential of −40 mV. Drugs were applied by superfusion without alteration of the perfusion rate and temperature. NMDA (100 μm) was applied to slices for 30 s. Tetrodotoxin (0.5 μm) was used in a subset of experiments. Drugs were purchased as follows: bupivacaine hydrochloride, lidocaine hydrochloride, NMDA, and GDP-β-S from Sigma-Aldrich (St. Louis, MO); tetrodotoxin and LaCl3from Wako (Osaka, Japan); and mepivacaine hydrochloride and ropivacaine hydrochloride from AstraZeneca (Osaka, Japan).
Statistical Analysis
Data are expressed as mean ± SD. Statistical significance was determined as P  < 0.05 using either the Student paired t  test or one-way analysis of variance.
Results
To study the effects of bupivacaine on excitatory synaptic transmission, whole-cell patch-clamp recordings were made from 80 rat SG neurons. Bupivacaine did not alter the level of holding current required to maintain neurons at −40 mV.
Bupivacaine Inhibits NMDA Receptor–mediated Responses
Exogenous application of NMDA (100 μm, 30 s) elicited an inward current at −40 mV (fig. 1), reflecting the activation of NMDA receptors. Preapplication of bupivacaine for 3 min reduced the amplitudes of NMDA-induced currents to 75 ± 8% (0.5 mm, n = 6; P  < 0.01; figs. 1A and C) and 53 ± 18% (2 mm, n = 10; P  < 0.01; figs. 1B and C) of the control values, respectively. These effects of bupivacaine were reversible and the amplitudes of currents recovered to the control values within 5–10 min (fig. 1D), although the effect of bupivacaine on voltage-gated sodium channels was longer lasting.11 
Fig. 1. Bupivacaine (Bup) inhibits the response to exogenous N  -methyl-d-aspartate (NMDA). (A  , B  , and D  ) Representative traces of NMDA-induced current, recorded at −40 mV before, during, and after bupivacaine application. Bupivacaine (0.5 mm, 2 mm) reversibly inhibited NMDA-induced currents. (C  ) The relative amplitudes were 75 ± 8% of the control level in the presence of 0.5 mm bupivacaine and 53 ± 18% in the presence of 2 mm bupivacaine. *P  < 0.01.
Fig. 1. Bupivacaine (Bup) inhibits the response to exogenous N 
	-methyl-d-aspartate (NMDA). (A 
	, B 
	, and D 
	) Representative traces of NMDA-induced current, recorded at −40 mV before, during, and after bupivacaine application. Bupivacaine (0.5 mm, 2 mm) reversibly inhibited NMDA-induced currents. (C 
	) The relative amplitudes were 75 ± 8% of the control level in the presence of 0.5 mm bupivacaine and 53 ± 18% in the presence of 2 mm bupivacaine. *P 
	< 0.01.
Fig. 1. Bupivacaine (Bup) inhibits the response to exogenous N  -methyl-d-aspartate (NMDA). (A  , B  , and D  ) Representative traces of NMDA-induced current, recorded at −40 mV before, during, and after bupivacaine application. Bupivacaine (0.5 mm, 2 mm) reversibly inhibited NMDA-induced currents. (C  ) The relative amplitudes were 75 ± 8% of the control level in the presence of 0.5 mm bupivacaine and 53 ± 18% in the presence of 2 mm bupivacaine. *P  < 0.01.
×
Tetrodotoxin, a Sodium Channel Blocker, or La3+, a Voltage-gated Ca2+Channel Blocker, Does Not Affect NMDA Receptor–mediated Responses
To test the possibility that the observed effects were not specific for bupivacaine, we used tetrodotoxin, a sodium channel blocker. Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents (101 ± 18% of control, n = 8; P  = 0.82; figs. 2A and B). In addition, we further investigated the effects of bupivacaine on NMDA-induced currents in the presence of tetrodotoxin. As expected, bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents (59 ± 10% of control, n = 5; P  < 0.01; figs. 2A and B), as it did in the absence of tetrodotoxin. Moreover, we used La3+(30 μm) to block the Ca2+entry through voltage-gated Ca2+channels.12 La3+could not affect NMDA-induced currents (106 ± 26% of control, n = 11; P  = 0.49; fig. 2C), however, bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents (61 ± 13% of control, n = 7; P  < 0.01; fig. 2C) even in the presence of La3+. Therefore, the observed current inhibition by bupivacaine is not likely to occur via  blockage of sodium channels or voltage-gated Ca2+channels.
Fig. 2. Effect of tetrodotoxin (TTX) and La3+(La) on N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents. However, bupivacaine (Bup; 2 mm) inhibited NMDA-induced currents in the presence of tetrodotoxin. (B  ) The relative amplitudes were 101 ± 18% of the control level in the presence of tetrodotoxin and 59 ± 10% in the presence of tetrodotoxin + 2 mm bupivacaine. (C  ) La3+(30 μm) could not affect NMDA-induced currents, but bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents in the presence of La3+. The relative amplitudes were 106 ± 26% of the control level in the presence of La3+and 61 ± 13% of control level in the presence of La3++ 2 mm bupivacaine. *P  < 0.01. NS = not significant.
Fig. 2. Effect of tetrodotoxin (TTX) and La3+(La) on N 
	-methyl-d-aspartate (NMDA)–induced currents. (A 
	) Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents. However, bupivacaine (Bup; 2 mm) inhibited NMDA-induced currents in the presence of tetrodotoxin. (B 
	) The relative amplitudes were 101 ± 18% of the control level in the presence of tetrodotoxin and 59 ± 10% in the presence of tetrodotoxin + 2 mm bupivacaine. (C 
	) La3+(30 μm) could not affect NMDA-induced currents, but bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents in the presence of La3+. The relative amplitudes were 106 ± 26% of the control level in the presence of La3+and 61 ± 13% of control level in the presence of La3++ 2 mm bupivacaine. *P 
	< 0.01. NS = not significant.
Fig. 2. Effect of tetrodotoxin (TTX) and La3+(La) on N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents. However, bupivacaine (Bup; 2 mm) inhibited NMDA-induced currents in the presence of tetrodotoxin. (B  ) The relative amplitudes were 101 ± 18% of the control level in the presence of tetrodotoxin and 59 ± 10% in the presence of tetrodotoxin + 2 mm bupivacaine. (C  ) La3+(30 μm) could not affect NMDA-induced currents, but bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents in the presence of La3+. The relative amplitudes were 106 ± 26% of the control level in the presence of La3+and 61 ± 13% of control level in the presence of La3++ 2 mm bupivacaine. *P  < 0.01. NS = not significant.
×
Bupivacaine Inhibits NMDA Receptor–mediated Responses in Different pH Conditions
To test whether the above actions of bupivacaine are dependent on the level of H+, we further examined the effects of bupivacaine on NMDA-induced currents at several different pH values (pH 7.0 or 8.0). Bupivacaine (2 mm) was dissolved in Krebs solution and titrated by HCl or NaOH up to pH 7.0 or 8.0. Before titration, the pH of the bupivacaine solution was approximately 7.4. The amplitudes of NMDA-induced currents were reduced by bupivacaine to 43 ± 13% of the control level (n = 7; P  < 0.01) at pH 7.0 and 58 ± 21% of the control level (n = 6; P  < 0.01; fig. 3) at pH 8.0. However, no significant inhibitory effects of bupivacaine on NMDA-induced currents were seen by one-way analysis of variance among the three groups (pH 7.0, 7.4, and 8.0; P  = 0.30).
Fig. 3. Bupivacaine inhibits the response to exogenous N  -methyl-d-aspartate (NMDA) in substantia gelatinosa neurons in different pH conditions. (A  and B  ) Bupivacaine (Bup; 2 mm) reversibly inhibited NMDA-induced currents under pH 7.0 or pH 8.0 conditions. (C  ) The relative amplitudes were 43 ± 13% of the control level at pH 7.0 and 58 ± 21% at pH 8.0. Comparison of the inhibitory effects of bupivacaine among the three groups (pH 7.0, 7.4, and 8.0) showed that the levels of inhibition were the same (P  = 0.30, one-way analysis of variance). *P  < 0.01.
Fig. 3. Bupivacaine inhibits the response to exogenous N 
	-methyl-d-aspartate (NMDA) in substantia gelatinosa neurons in different pH conditions. (A 
	and B 
	) Bupivacaine (Bup; 2 mm) reversibly inhibited NMDA-induced currents under pH 7.0 or pH 8.0 conditions. (C 
	) The relative amplitudes were 43 ± 13% of the control level at pH 7.0 and 58 ± 21% at pH 8.0. Comparison of the inhibitory effects of bupivacaine among the three groups (pH 7.0, 7.4, and 8.0) showed that the levels of inhibition were the same (P 
	= 0.30, one-way analysis of variance). *P 
	< 0.01.
Fig. 3. Bupivacaine inhibits the response to exogenous N  -methyl-d-aspartate (NMDA) in substantia gelatinosa neurons in different pH conditions. (A  and B  ) Bupivacaine (Bup; 2 mm) reversibly inhibited NMDA-induced currents under pH 7.0 or pH 8.0 conditions. (C  ) The relative amplitudes were 43 ± 13% of the control level at pH 7.0 and 58 ± 21% at pH 8.0. Comparison of the inhibitory effects of bupivacaine among the three groups (pH 7.0, 7.4, and 8.0) showed that the levels of inhibition were the same (P  = 0.30, one-way analysis of variance). *P  < 0.01.
×
Bupivacaine Inhibits NMDA Receptor–mediated Responses without Activation of G Proteins
There are a few reports investigating the interactions between local anesthetics and G protein–coupled receptors.6,13,14 We therefore examined to determine whether G proteins are responsible for the observed effect of bupivacaine. GDP-β-S (1 mm), a G-protein inhibitor that competitively inhibits G-proteins, was added to the pipette solution to prevent the postsynaptic activation of G proteins.15–17 NMDA-induced currents were recorded just after establishing the whole-cell configuration (fig. 4A). These currents did not change when NMDA was again applied 15 min later (92 ± 4% of control, n = 4; P  = 0.26). However, these currents were reduced in the presence of bupivacaine (2 mm, 50 ± 7% of control, n = 4; P  < 0.01; figs. 4A and B). These findings suggested that the observed current inhibition by bupivacaine was not mediated by the activation of G proteins.
Fig. 4. Effect of a G-protein blocker on the inhibition of N  -methyl-d-aspartate (NMDA)–induced currents by bupivacaine. (A  ) Intrapipette administration of the G-protein blocker guanosine-5′-O  -(2-thiodiphosphate) (GDP-β-S; 1 mm) did not block the reduction of NMDA-induced currents by bupivacaine (2 mm). (B  ) The amplitudes of NMDA-induced currents decreased to 50 ± 7% of the control level (just after establishing the whole-cell configuration). *P  < 0.01.
Fig. 4. Effect of a G-protein blocker on the inhibition of N 
	-methyl-d-aspartate (NMDA)–induced currents by bupivacaine. (A 
	) Intrapipette administration of the G-protein blocker guanosine-5′-O 
	-(2-thiodiphosphate) (GDP-β-S; 1 mm) did not block the reduction of NMDA-induced currents by bupivacaine (2 mm). (B 
	) The amplitudes of NMDA-induced currents decreased to 50 ± 7% of the control level (just after establishing the whole-cell configuration). *P 
	< 0.01.
Fig. 4. Effect of a G-protein blocker on the inhibition of N  -methyl-d-aspartate (NMDA)–induced currents by bupivacaine. (A  ) Intrapipette administration of the G-protein blocker guanosine-5′-O  -(2-thiodiphosphate) (GDP-β-S; 1 mm) did not block the reduction of NMDA-induced currents by bupivacaine (2 mm). (B  ) The amplitudes of NMDA-induced currents decreased to 50 ± 7% of the control level (just after establishing the whole-cell configuration). *P  < 0.01.
×
Lidocaine, Ropivacaine, and Mepivacaine Also Inhibit NMDA Receptor–mediated Responses
To test whether other local anesthetics inhibit NMDA-induced currents like bupivacaine, we used lidocaine, ropivacaine, and mepivacaine. NMDA-induced currents were also inhibited by lidocaine (2 mm, 72 ± 19% of control, n = 5; P  < 0.05), ropivacaine (2 mm, 61 ± 19% of control, n = 5; P  < 0.01), and mepivacaine (2 mm, 74 ± 15% of control, n = 6; P  < 0.01), shown in figures 5A and B. These local anesthetics other than bupivacaine also inhibited NMDA-induced currents, suggesting that the inhibition was not specific for bupivacaine.
Fig. 5. Lidocaine (Lid), ropivacaine (Rop), and mepivacaine (Mep) inhibit N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) NMDA-induced currents were also inhibited by lidocaine (2 mm), ropivacaine (2 mm), and mepivacaine (2 mm). (B  ) The relative amplitudes were 72 ± 19% (2 mm lidocaine), 61 ± 19% (2 mm ropivacaine), and 74 ± 15% (2 mm mepivacaine) of control level, respectively. *P  < 0.01. # P  < 0.05.
Fig. 5. Lidocaine (Lid), ropivacaine (Rop), and mepivacaine (Mep) inhibit N 
	-methyl-d-aspartate (NMDA)–induced currents. (A 
	) NMDA-induced currents were also inhibited by lidocaine (2 mm), ropivacaine (2 mm), and mepivacaine (2 mm). (B 
	) The relative amplitudes were 72 ± 19% (2 mm lidocaine), 61 ± 19% (2 mm ropivacaine), and 74 ± 15% (2 mm mepivacaine) of control level, respectively. *P 
	< 0.01. # P 
	< 0.05.
Fig. 5. Lidocaine (Lid), ropivacaine (Rop), and mepivacaine (Mep) inhibit N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) NMDA-induced currents were also inhibited by lidocaine (2 mm), ropivacaine (2 mm), and mepivacaine (2 mm). (B  ) The relative amplitudes were 72 ± 19% (2 mm lidocaine), 61 ± 19% (2 mm ropivacaine), and 74 ± 15% (2 mm mepivacaine) of control level, respectively. *P  < 0.01. # P  < 0.05.
×
Discussion
This is the first study to show the inhibition of NMDA-induced currents by bupivacaine electrophysiologically in the SG. The SG is thought to play an important role in modulating nociceptive transmission. The inhibitory effect lasted for several minutes only, despite being known as a “long-lasting” local anesthetic. Similarly, lidocaine, ropivacaine, and mepivacaine also inhibited NMDA-induced currents. However, tetrodotoxin and La3+did not affect these currents. In addition, mixing a G-protein blocker with the pipette solution did not block the inhibition of NMDA-induced currents by bupivacaine. These results suggest that inhibition of voltage-gated sodium channels, voltage-gated Ca2+channels, or G proteins is not the mechanism by which bupivacaine modulates these currents.
Some investigators have reported the interactions between NMDA receptors and local anesthetics.3–6 In these reports, bupivacaine exerted inhibitory effects toward NMDA-induced responses. The obtained IC50values of bupivacaine were 1.0 in Xenopus  oocytes3 and 2.8 mm in mouse CA1 pyramidal neurons,5 respectively. Hahnenkamp et al.  4 reported that they could not calculate IC50because the inhibition of currents did not exceed 50% in the presence of 0.1 mm bupivacaine. Furthermore, bupivacaine (2 mm) reduced NMDA-induced phosphorylated extracellular signal–regulated kinase activation to 59% of the control levels.6 These concentrations and the inhibitory potency of bupivacaine correspond to our data and suggest that bupivacaine exerts an inhibitory effect on NMDA-induced responses in the millimolar concentration range, even though bupivacaine blocks voltage-gated sodium channels at micromolar levels for as long as 30 min in rat dorsal horn neurons.11 We used a racemic mixture of bupivacaine in this study and did not examine the difference between levobupivacaine and dextrabupivacaine. Ueta et al.  18 reported that the inhibitory effects of racemic bupivacaine and its enantiomers were similar at NMDA receptors in Xenopus  oocytes. However, Hahnenkamp et al.  4 reported that S  (−)-ropivacaine inhibited NMDA signaling, whereas R  (+)-ropivacaine was without effect. Therefore, there remains the possibility that the stereoselectivity may contribute to the inhibition of NMDA-induced current in the dorsal horn.
The concentration of 0.5% bupivacaine, widely used in spinal anesthesia, is approximately 15 mm. There are several reports about the concentrations of local anesthetics in cerebrospinal fluid (CSF) after spinal or epidural injection. In humans, the CSF concentration of bupivacaine ranged from 0.1 to 3 mm after injection of plain bupivacaine (17.5 or 20 mg),19 whereas that of bupivacaine after epidural administration (150 mg) was up to approximately 0.1 mm.20 Moreover, the maximal CSF concentration of tetracaine after intrathecal administration was 0.7 mm.21 In addition, Kamiya et al.  22 reported that the CSF concentration of lidocaine 10 min after epidural administration of 100 mg was around 0.25 mm. Similarly, the CSF concentration was in the millimolar range after intrathecal or epidural administration of bupivacaine and other local anesthetics in animals.23–25 The intraspinal concentration of local anesthetics after intrathecal injection should be lower than that in CSF, but superficial dorsal horn neurons would receive a relatively higher concentration, close to the CSF concentration. These investigations indicate that the concentrations of bupivacaine used in this study are clinically relevant during spinal anesthesia. Studies using an in vivo  model will be valuable to confirm whether its concentration is relevant during spinal anesthesia.
Local anesthetics have also been reported to have an inhibitory effect on other ion channel–coupled receptors, including 5-hydroxytryptamine type 3,26 γ-aminobutyric acid, glycine,27 and nicotinic acetylcholine18 receptors. These broad actions of bupivacaine suggest that it may act on membrane phospholipids but not at any defined sites on receptors, because its potency is low and it is not specific among ionotropic receptors.6 However, we observed that bupivacaine inhibited NMDA-induced inward currents, i.e.  , cation influx, in this study. This suggests that bupivacaine directly inhibits NMDA receptor–coupled channels and prevents depolarization of dorsal horn neurons. On the other hand, there are a few reports investigating the interactions between local anesthetics and GPCRs. For example, local anesthetics can affect guanosine triphosphate–binding proteins.13 Local anesthetics inhibit certain GPCRs (lysophosphatidic acid, thromboxane A2, platelet-activating factor, and m1 muscarinic receptors) expressed in Xenopus  oocytes.14 However, Yanagidate et al.  6 reported that bupivacaine did not attenuate phosphorylated extracellular signal–regulated kinase activation by GPCR agonists like substance P, bradykinin, and (R  , S  )-3,5-dihydroxyphenylglycine (an agonist of metabotropic glutamate receptors). Similarly, in our study, G proteins were not involved in the inhibition of NMDA-induced responses by bupivacaine. Therefore, local anesthetics might inhibit ion channel–coupled receptors more potently than they inhibit GPCRs.
It has been known that an increase in the pH of local anesthetics accelerates the onset and decreases the required concentration to block nerve conduction due to increasing the amount of drug in the uncharged base form,28 which diffuses easily across the nerve membrane. However, Hahnenkamp et al.  4 reported that intracellular QX314 and extracellular benzocaine inhibited NMDA-induced currents, but that extracellular QX314 produced no such inhibition. QX314 is a permanently charged and non–membrane-permeable lidocaine analog, and benzocaine is a completely uncharged local anesthetic in physiologic conditions. They concluded that the site of action of local anesthetics toward NMDA-induced currents is intracellular and charge independent. Although we did not examine the charge independency by bupivacaine in this study, this charge independency for inhibiting the current is consistent with our data, because the inhibition of NMDA-induced currents by bupivacaine did not change in different pH conditions.
There was a paradox between the dependence of local anesthetic function on charge and pH, but not its interaction with NMDA receptors. It is suggested that bupivacaine may have the different route to reach its effect site to inhibit NMDA-induced currents. However, there remains the possibility that we could not detect the charge dependency because there is little difference in the amount of uncharged base form between pH 7.0 and 8.0. However, we did not examine the lower or higher pH conditions because we were afraid that neurons may not survive in those conditions.
N  -methyl-d-aspartate receptors play an important role in central sensitization regarding long-term pain.1,2 Therefore, NMDA receptor antagonism results in an antinociceptive effect, especially in patients with chronic pain, although there is little evidence that NMDA receptor antagonism is involved in antinociceptive effect of local anesthetics. Local anesthetics have been widely used in these patients via  neuraxial blockade or intravenous administration and have provided them with pain relief. These effects have been discussed from one aspect, sodium channel blockade, but our study suggests that not only sodium channel blockade but also the NMDA receptor antagonism of bupivacaine may have the possibility to prevent these patients from developing chronic pain. However, we think that studies using intrathecal application of bupivacaine in vivo  will be required to fully understand the physiologic implication of NMDA receptor antagonism by bupivacaine.
In summary, the current study suggests that bupivacaine inhibits NMDA-induced glutamatergic transmission in rat dorsal horn neurons and that this inhibition is not affected by sodium channel blockers, Ca2+channel blockers, G-protein blockers, or different pH conditions. This suggests that not only voltage-gated sodium channels but also glutamate NMDA receptors are important for the analgesia induced by bupivacaine and other local anesthetics, especially during spinal and epidural anesthesia.
References
South SM, Kohno T, Kaspar BK, Hegarty D, Vissel B, Drake CT, Ohata M, Jenab S, Sailer AW, Malkmus S, Masuyama T, Horner P, Bogulavsky J, Gage FH, Yaksh TL, Woolf CJ, Heinemann SF, Inturrisi CE: A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci 2003; 23:5031–40South, SM Kohno, T Kaspar, BK Hegarty, D Vissel, B Drake, CT Ohata, M Jenab, S Sailer, AW Malkmus, S Masuyama, T Horner, P Bogulavsky, J Gage, FH Yaksh, TL Woolf, CJ Heinemann, SF Inturrisi, CE
Ji RR, Kohno T, Moore KA, Woolf CJ: Central sensitization and LTP: Do pain and memory share similar mechanisms? Trends Neurosci 2003; 26:696–705Ji, RR Kohno, T Moore, KA Woolf, CJ
Sugimoto M, Uchida I, Mashimo T: Local anaesthetics have different mechanisms and sites of action at the recombinant N-methyl-D-aspartate (NMDA) receptors. Br J Pharmacol 2003; 138:876–82Sugimoto, M Uchida, I Mashimo, T
Hahnenkamp K, Durieux ME, Hahnenkamp A, Schauerte SK, Hoenemann CW, Vegh V, Theilmeier G, Hollmann MW: Local anaesthetics inhibit signalling of human NMDA receptors recombinantly expressed in Xenopus laevis  oocytes: Role of protein kinase C. Br J Anaesth 2006; 96:77–87Hahnenkamp, K Durieux, ME Hahnenkamp, A Schauerte, SK Hoenemann, CW Vegh, V Theilmeier, G Hollmann, MW
Nishizawa N, Shirasaki T, Nakao S, Matsuda H, Shingu K: The inhibition of the N-methyl-D-aspartate receptor channel by local anesthetics in mouse CA1 pyramidal neurons. Anesth Analg 2002; 94:325–30Nishizawa, N Shirasaki, T Nakao, S Matsuda, H Shingu, K
Yanagidate F, Strichartz GR: Bupivacaine inhibits activation of neuronal spinal extracellular receptor–activated kinase through selective effects on ionotropic receptors. Anesthesiology 2006; 104:805–14Yanagidate, F Strichartz, GR
Kumazawa T, Perl ER: Excitation of marginal and substantia gelatinosa neurons in the primate spinal cord: Indications of their place in dorsal horn functional organization. J Comp Neurol 1978; 177:417–34Kumazawa, T Perl, ER
Yoshimura M, Nishi S: Blind patch-clamp recordings from substantia gelatinosa neurons in adult rat spinal cord slices: Pharmacological properties of synaptic currents. Neuroscience 1993; 53:519–26Yoshimura, M Nishi, S
Kohno T, Wakai A, Ataka T, Ikoma M, Yamakura T, Baba H: Actions of midazolam on excitatory transmission in dorsal horn neurons of adult rat spinal cord. Anesthesiology 2006; 104:338–43Kohno, T Wakai, A Ataka, T Ikoma, M Yamakura, T Baba, H
Kohno T, Wang H, Amaya F, Brenner GJ, Cheng JK, Ji RR, Woolf CJ: Bradykinin enhances AMPA and NMDA receptor activity in spinal cord dorsal horn neurons by activating multiple kinases to produce pain hypersensitivity. J Neurosci 2008; 28:4533–40Kohno, T Wang, H Amaya, F Brenner, GJ Cheng, JK Ji, RR Woolf, CJ
Olschewski A, Hempelmann G, Vogel W, Safronov BV: Blockade of Na+and K+currents by local anesthetics in the dorsal horn neurons of the spinal cord. Anesthesiology 1998; 88:172–9Olschewski, A Hempelmann, G Vogel, W Safronov, BV
Nakatsuka T, Gu JG: ATP P2X receptor-mediated enhancement of glutamate release and evoked EPSCs in dorsal horn neurons of the rat spinal cord. J Neurosci 2001; 21:6522–31Nakatsuka, T Gu, JG
Hageluken A, Grunbaum L, Nurnberg B, Harhammer R, Schunack W, Seifert R: Lipophilic beta-adrenoceptor antagonists and local anesthetics are effective direct activators of G-proteins. Biochem Pharmacol 1994; 47:1789–95Hageluken, A Grunbaum, L Nurnberg, B Harhammer, R Schunack, W Seifert, R
Hollmann MW, Herroeder S, Kurz KS, Hoenemann CW, Struemper D, Hahnenkamp K, Durieux ME: Time-dependent inhibition of G protein–coupled receptor signaling by local anesthetics. Anesthesiology 2004; 100:852–60Hollmann, MW Herroeder, S Kurz, KS Hoenemann, CW Struemper, D Hahnenkamp, K Durieux, ME
Wang H, Kohno T, Amaya F, Brenner GJ, Ito N, Allchorne A, Ji RR, Woolf CJ: Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci 2005; 25:7986–92Wang, H Kohno, T Amaya, F Brenner, GJ Ito, N Allchorne, A Ji, RR Woolf, CJ
Ishii H, Kohno T, Yamakura T, Ikoma M, Baba H: Action of dexmedetomidine on the substantia gelatinosa neurons of the rat spinal cord. Eur J Neurosci 2008; 27:3182–90Ishii, H Kohno, T Yamakura, T Ikoma, M Baba, H
Nakatsuka T, Fujita T, Inoue K, Kumamoto E: Activation of GIRK channels in substantia gelatinosa neurones of the adult rat spinal cord: A possible involvement of somatostatin. J Physiol 2008; 586:2511–22Nakatsuka, T Fujita, T Inoue, K Kumamoto, E
Ueta K, Sugimoto M, Suzuki T, Uchida I, Mashimo T: In vitro  antagonism of recombinant ligand-gated ion-channel receptors by stereospecific enantiomers of bupivacaine. Reg Anesth Pain Med 2006; 31:19–25Ueta, K Sugimoto, M Suzuki, T Uchida, I Mashimo, T
Ruppen W, Steiner LA, Drewe J, Hauenstein L, Brugger S, Seeberger MD: Bupivacaine concentrations in the lumbar cerebrospinal fluid of patients during spinal anaesthesia. Br J Anaesth 2009; 102:832–8Ruppen, W Steiner, LA Drewe, J Hauenstein, L Brugger, S Seeberger, MD
Wilkinson GR, Lund PC: Bupivacaine levels in plasma and cerebrospinal fluid following peridural administration. Anesthesiology 1970; 33:482–6Wilkinson, GR Lund, PC
Converse JG, Landmesser CM, Harmel MH: The concentration of pontocaine hydrochloride in the cerebrospinal fluid during spinal anesthesia, and the influence of epinephrine in prolonging the sensory anesthetic effect. Anesthesiology 1954; 15:1–10Converse, JG Landmesser, CM Harmel, MH
Kamiya Y, Kikuchi T, Inagawa G, Miyazaki H, Miura M, Morita S, Goto T: Lidocaine concentration in cerebrospinal fluid after epidural administration: A comparison between epidural and combined spinal–epidural anesthesia. Anesthesiology 2009; 110:1127–32Kamiya, Y Kikuchi, T Inagawa, G Miyazaki, H Miura, M Morita, S Goto, T
Rose FX, Estebe JP, Ratajczak M, Wodey E, Chevanne F, Dollo G, Bec D, Malinovsky JM, Ecoffey C, Le Corre P: Epidural, intrathecal pharmacokinetics, and intrathecal bioavailability of ropivacaine. Anesth Analg 2007; 105:859–67Rose, FX Estebe, JP Ratajczak, M Wodey, E Chevanne, F Dollo, G Bec, D Malinovsky, JM Ecoffey, C Le Corre, P
Bernards CM: Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 2006; 105:169–78Bernards, CM
Clement R, Malinovsky JM, Le Corre P, Dollo G, Chevanne F, Le Verge R: Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. J Pharmacol Exp Ther 1999; 289:1015–21Clement, R Malinovsky, JM Le Corre, P Dollo, G Chevanne, F Le Verge, R
Ueta K, Suzuki T, Sugimoto M, Uchida I, Mashimo T: Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med 2007; 32:462–70Ueta, K Suzuki, T Sugimoto, M Uchida, I Mashimo, T
Hara K, Sata T: The effects of the local anesthetics lidocaine and procaine on glycine and gamma-aminobutyric acid receptors expressed in Xenopus  oocytes. Anesth Analg 2007; 104:1434–9Hara, K Sata, T
Wong K, Strichartz GR, Raymond SA: On the mechanisms of potentiation of local anesthetics by bicarbonate buffer: Drug structure-activity studies on isolated peripheral nerve. Anesth Analg 1993; 76:131–43Wong, K Strichartz, GR Raymond, SA
Fig. 1. Bupivacaine (Bup) inhibits the response to exogenous N  -methyl-d-aspartate (NMDA). (A  , B  , and D  ) Representative traces of NMDA-induced current, recorded at −40 mV before, during, and after bupivacaine application. Bupivacaine (0.5 mm, 2 mm) reversibly inhibited NMDA-induced currents. (C  ) The relative amplitudes were 75 ± 8% of the control level in the presence of 0.5 mm bupivacaine and 53 ± 18% in the presence of 2 mm bupivacaine. *P  < 0.01.
Fig. 1. Bupivacaine (Bup) inhibits the response to exogenous N 
	-methyl-d-aspartate (NMDA). (A 
	, B 
	, and D 
	) Representative traces of NMDA-induced current, recorded at −40 mV before, during, and after bupivacaine application. Bupivacaine (0.5 mm, 2 mm) reversibly inhibited NMDA-induced currents. (C 
	) The relative amplitudes were 75 ± 8% of the control level in the presence of 0.5 mm bupivacaine and 53 ± 18% in the presence of 2 mm bupivacaine. *P 
	< 0.01.
Fig. 1. Bupivacaine (Bup) inhibits the response to exogenous N  -methyl-d-aspartate (NMDA). (A  , B  , and D  ) Representative traces of NMDA-induced current, recorded at −40 mV before, during, and after bupivacaine application. Bupivacaine (0.5 mm, 2 mm) reversibly inhibited NMDA-induced currents. (C  ) The relative amplitudes were 75 ± 8% of the control level in the presence of 0.5 mm bupivacaine and 53 ± 18% in the presence of 2 mm bupivacaine. *P  < 0.01.
×
Fig. 2. Effect of tetrodotoxin (TTX) and La3+(La) on N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents. However, bupivacaine (Bup; 2 mm) inhibited NMDA-induced currents in the presence of tetrodotoxin. (B  ) The relative amplitudes were 101 ± 18% of the control level in the presence of tetrodotoxin and 59 ± 10% in the presence of tetrodotoxin + 2 mm bupivacaine. (C  ) La3+(30 μm) could not affect NMDA-induced currents, but bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents in the presence of La3+. The relative amplitudes were 106 ± 26% of the control level in the presence of La3+and 61 ± 13% of control level in the presence of La3++ 2 mm bupivacaine. *P  < 0.01. NS = not significant.
Fig. 2. Effect of tetrodotoxin (TTX) and La3+(La) on N 
	-methyl-d-aspartate (NMDA)–induced currents. (A 
	) Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents. However, bupivacaine (Bup; 2 mm) inhibited NMDA-induced currents in the presence of tetrodotoxin. (B 
	) The relative amplitudes were 101 ± 18% of the control level in the presence of tetrodotoxin and 59 ± 10% in the presence of tetrodotoxin + 2 mm bupivacaine. (C 
	) La3+(30 μm) could not affect NMDA-induced currents, but bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents in the presence of La3+. The relative amplitudes were 106 ± 26% of the control level in the presence of La3+and 61 ± 13% of control level in the presence of La3++ 2 mm bupivacaine. *P 
	< 0.01. NS = not significant.
Fig. 2. Effect of tetrodotoxin (TTX) and La3+(La) on N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) Tetrodotoxin (0.5 μm) did not affect the amplitudes of NMDA-induced currents. However, bupivacaine (Bup; 2 mm) inhibited NMDA-induced currents in the presence of tetrodotoxin. (B  ) The relative amplitudes were 101 ± 18% of the control level in the presence of tetrodotoxin and 59 ± 10% in the presence of tetrodotoxin + 2 mm bupivacaine. (C  ) La3+(30 μm) could not affect NMDA-induced currents, but bupivacaine (2 mm) reduced the amplitudes of NMDA-induced currents in the presence of La3+. The relative amplitudes were 106 ± 26% of the control level in the presence of La3+and 61 ± 13% of control level in the presence of La3++ 2 mm bupivacaine. *P  < 0.01. NS = not significant.
×
Fig. 3. Bupivacaine inhibits the response to exogenous N  -methyl-d-aspartate (NMDA) in substantia gelatinosa neurons in different pH conditions. (A  and B  ) Bupivacaine (Bup; 2 mm) reversibly inhibited NMDA-induced currents under pH 7.0 or pH 8.0 conditions. (C  ) The relative amplitudes were 43 ± 13% of the control level at pH 7.0 and 58 ± 21% at pH 8.0. Comparison of the inhibitory effects of bupivacaine among the three groups (pH 7.0, 7.4, and 8.0) showed that the levels of inhibition were the same (P  = 0.30, one-way analysis of variance). *P  < 0.01.
Fig. 3. Bupivacaine inhibits the response to exogenous N 
	-methyl-d-aspartate (NMDA) in substantia gelatinosa neurons in different pH conditions. (A 
	and B 
	) Bupivacaine (Bup; 2 mm) reversibly inhibited NMDA-induced currents under pH 7.0 or pH 8.0 conditions. (C 
	) The relative amplitudes were 43 ± 13% of the control level at pH 7.0 and 58 ± 21% at pH 8.0. Comparison of the inhibitory effects of bupivacaine among the three groups (pH 7.0, 7.4, and 8.0) showed that the levels of inhibition were the same (P 
	= 0.30, one-way analysis of variance). *P 
	< 0.01.
Fig. 3. Bupivacaine inhibits the response to exogenous N  -methyl-d-aspartate (NMDA) in substantia gelatinosa neurons in different pH conditions. (A  and B  ) Bupivacaine (Bup; 2 mm) reversibly inhibited NMDA-induced currents under pH 7.0 or pH 8.0 conditions. (C  ) The relative amplitudes were 43 ± 13% of the control level at pH 7.0 and 58 ± 21% at pH 8.0. Comparison of the inhibitory effects of bupivacaine among the three groups (pH 7.0, 7.4, and 8.0) showed that the levels of inhibition were the same (P  = 0.30, one-way analysis of variance). *P  < 0.01.
×
Fig. 4. Effect of a G-protein blocker on the inhibition of N  -methyl-d-aspartate (NMDA)–induced currents by bupivacaine. (A  ) Intrapipette administration of the G-protein blocker guanosine-5′-O  -(2-thiodiphosphate) (GDP-β-S; 1 mm) did not block the reduction of NMDA-induced currents by bupivacaine (2 mm). (B  ) The amplitudes of NMDA-induced currents decreased to 50 ± 7% of the control level (just after establishing the whole-cell configuration). *P  < 0.01.
Fig. 4. Effect of a G-protein blocker on the inhibition of N 
	-methyl-d-aspartate (NMDA)–induced currents by bupivacaine. (A 
	) Intrapipette administration of the G-protein blocker guanosine-5′-O 
	-(2-thiodiphosphate) (GDP-β-S; 1 mm) did not block the reduction of NMDA-induced currents by bupivacaine (2 mm). (B 
	) The amplitudes of NMDA-induced currents decreased to 50 ± 7% of the control level (just after establishing the whole-cell configuration). *P 
	< 0.01.
Fig. 4. Effect of a G-protein blocker on the inhibition of N  -methyl-d-aspartate (NMDA)–induced currents by bupivacaine. (A  ) Intrapipette administration of the G-protein blocker guanosine-5′-O  -(2-thiodiphosphate) (GDP-β-S; 1 mm) did not block the reduction of NMDA-induced currents by bupivacaine (2 mm). (B  ) The amplitudes of NMDA-induced currents decreased to 50 ± 7% of the control level (just after establishing the whole-cell configuration). *P  < 0.01.
×
Fig. 5. Lidocaine (Lid), ropivacaine (Rop), and mepivacaine (Mep) inhibit N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) NMDA-induced currents were also inhibited by lidocaine (2 mm), ropivacaine (2 mm), and mepivacaine (2 mm). (B  ) The relative amplitudes were 72 ± 19% (2 mm lidocaine), 61 ± 19% (2 mm ropivacaine), and 74 ± 15% (2 mm mepivacaine) of control level, respectively. *P  < 0.01. # P  < 0.05.
Fig. 5. Lidocaine (Lid), ropivacaine (Rop), and mepivacaine (Mep) inhibit N 
	-methyl-d-aspartate (NMDA)–induced currents. (A 
	) NMDA-induced currents were also inhibited by lidocaine (2 mm), ropivacaine (2 mm), and mepivacaine (2 mm). (B 
	) The relative amplitudes were 72 ± 19% (2 mm lidocaine), 61 ± 19% (2 mm ropivacaine), and 74 ± 15% (2 mm mepivacaine) of control level, respectively. *P 
	< 0.01. # P 
	< 0.05.
Fig. 5. Lidocaine (Lid), ropivacaine (Rop), and mepivacaine (Mep) inhibit N  -methyl-d-aspartate (NMDA)–induced currents. (A  ) NMDA-induced currents were also inhibited by lidocaine (2 mm), ropivacaine (2 mm), and mepivacaine (2 mm). (B  ) The relative amplitudes were 72 ± 19% (2 mm lidocaine), 61 ± 19% (2 mm ropivacaine), and 74 ± 15% (2 mm mepivacaine) of control level, respectively. *P  < 0.01. # P  < 0.05.
×